IASO Bio Acquires MediSix Therapeutics

IASO Biotechnology has completed its acquisition of MediSix Therapeutics, a Singapore-based immune cell engineering and cell therapy company.

This acquisition marks a key milestone in IASO Bio’s globalization strategy. By integrating MediSix’s differentiated T-cell engineering platform, R&D pipeline, and international talent team with IASO Bio’s cell therapy, manufacturing and commercialization capabilities, IASO Bio will further strengthen its global R&D and operational systems and accelerate the international development and commercialization of innovative cell therapy products.

MediSix’s core technology focuses on addressing key challenges in cell therapy for T-cell malignancies. Its proprietary PEBL (Protein Expression Blocker) platform can specifically block the expression of target proteins on cell surfaces, effectively reducing fratricide among CAR-T cells. This enables targeting of antigens shared between T cells and target cells, and by combining ex vivo and in vivo CAR-T approaches, has established exclusive technological barriers and advantages for treating hematologic malignancies, solid tumors, and other diseases.

MediSix has also developed a differentiated pipeline addressing multiple unmet clinical needs. Its lead program, IASO107 (formerly PCART7), is undergoing clinical evaluation in collaboration with leading international recognized research hospitals, and early clinical experience has shown promising efficacy and safety signals.

Zhang Jinhua, Founder, Chairwoman and CEO of IASO Bio, said, “This acquisition represents a major milestone in the company’s globalization strategy. MediSix has an outstanding scientific team and a differentiated PEBL technology platform with unique advantages in T-cell malignancies and AML that strongly complement IASO Bio’s existing pipeline.”

According to Jinhua, following this acquisition, MediSix will continue to develop follow-on products leveraging its unique platform, while harnessing IASO Bio’s cost advantages and execution efficiency in CMC and clinical development to accelerate its international development. Furthermore, the addition of MediSix’s international team will significantly enhance IASO Bio’s R&D capabilities, talent attraction, and global collaboration network in the cell therapy field.

Mike Carusi, Chairman of MediSix and Managing Partner of Lightstone Ventures, said, “IASO Bio brings a proven full-process platform, deep CMC and clinical development expertise, and a demonstrated track record of advancing a CAR-T therapy from the laboratory to commercial approval — a strong complement to MediSix’s PEBL platform and T-cell engineering strengths. On this foundation, we expect MediSix’s clinical programs to accelerate, with the combined capabilities of both companies offering significant value over the long term.”

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.